

# AssayMax™ Human Interferon alpha-2b ELISA Kit

Assaypro LLC 3400 Harry S Truman Blvd St. Charles, MO 63301 T (636) 447-9175 F (636) 395-7419 www.assaypro.com

For any questions regarding troubleshooting or performing the assay, please contact our support team at support@assaypro.com.

Thank you for choosing Assaypro.

### **Assay Summary**

**Step 1**. Add 50  $\mu$ l of Standard or Sample per well. Incubate 2 hours.

Step 2. Wash, then add 50  $\mu l$  of Biotinylated Antibody per well. Incubate 1 hour.

Step 3. Wash, then add 50  $\mu l$  of SP Conjugate per well. Incubate 30 minutes.

**Step 4.** Wash, then add 50  $\mu$ l of Chromogen Substrate per well. Incubate 15 minutes.

**Step 5.** Add 50  $\mu$ l of Stop Solution per well. Read at 450 nm immediately.

## Symbol Key

Consult instructions for use.

## Assay Template

12								
11								
10								
6								
8								
7								
9								
ß								
4								
m								
2								
1								
	A	B	С	D	Е	ł	Ð	н

## AssayMax<sup>™</sup> Human Interferon alpha-2b ELISA Kit

Catalog No. El3030-1 Sample insert for reference use only

#### Introduction

Interferon alpha-2b (IFN alpha-2b), also known as interferon alpha-A (LeIF A), and interferon alpha-2 (IFN alpha-2), belongs to the type I interferon family. The mature protein contains 165 amino acids with a molecular mass of 19 kDa (1). It exists in the crystal as a noncovalent dimer, which associates in a novel manner. Unlike other structurally characterized cytokines, zinc ion mediates extensive interactions in the dimer interface (2). It binds to interferon cell receptors type I and is encoded on chromosome 9. The heterodimeric alpha receptor consists of two subunits, IFNAR1 and IFNAR2, associating upon binding of interferon. The IFNAR2 subunit is the major ligand-binding component and can bind to IFN alpha-2b with high affinity. As a helical cytokine, IFN alpha-2b is produced by leukocytes in response to viral infections and has antiviral, antibacterial, antiproliferative, immunomodulatory, and cell growth regulatory activities (3-4).

#### **Principle of the Assay**

The AssayMax<sup>™</sup> Human Interferon alpha-2b ELISA (Enzyme-Linked Immunosorbent Assay) Kit is designed for detection of IFN alpha-2b in human **plasma, serum, and cell culture samples**. This assay employs a quantitative **sandwich enzyme immunoassay** technique that measures human IFN alpha-2b in approximately 4 hours. A polyclonal antibody specific for human IFN alpha-2b has been pre-coated onto a 96-well microplate with removable strips. IFN alpha-2b in standards and samples is sandwiched by the immobilized antibody and a biotinylated polyclonal antibody specific for human IFN alpha-2b, which is recognized by a streptavidin-peroxidase (SP) conjugate. All unbound material is washed away and a peroxidase enzyme substrate is added. The color development is stopped and the intensity of the color is measured.

#### **Caution and Warning**

• This product is for **Research Use Only** and is not intended for use in diagnostic procedures.

- Prepare all reagents (diluent buffer, wash buffer, standard, biotinylated antibody, and SP conjugate), as instructed, prior to running the assay.
- Prepare all samples prior to running the assay. The dilution factors for the samples are suggested in this insert. However, the user should determine the optimal dilution factor.
- Spin down the SP conjugate vial, the biotinylated antibody vial, and the standard diluent vial before opening and using contents.
- The Stop Solution is an acidic solution.
- The kit should not be used beyond the expiration date.

#### Reagents

- Human IFN alpha-2b Microplate: A 96-well polystyrene microplate (12 strips of 8 wells) coated with a polyclonal antibody against human IFN alpha-2b.
- Sealing Tapes: Each kit contains 3 precut, pressure sensitive sealing tapes that can be cut to fit the format of the individual assay.
- Human IFN alpha-2b Standard: Human IFN alpha-2b in a buffered protein base (5600 pg, lyophilized).
- Biotinylated Human IFN alpha-2b Antibody (50x): A 50-fold concentrated biotinylated polyclonal antibody against human IFN alpha-2b (120 μl).
- MIX Diluent Concentrate (10x): A 10-fold concentrated buffered protein base (30 ml).
- Standard Diluent (1x): A buffered protein base with stabilizer (2 ml).
- Wash Buffer Concentrate (20x): A 20-fold concentrated buffered surfactant (30 ml, 2 bottles).
- SP Conjugate (100x): A 100-fold concentrate (80 µl).
- **Chromogen Substrate (1x):** A stabilized peroxidase chromogen substrate tetramethylbenzidine (7 ml).
- Stop Solution (1x): A 0.5 N hydrochloric acid solution to stop the chromogen substrate reaction (11 ml).

#### Storage Condition

- Upon arrival, immediately store components of the kit at recommended temperatures up to the expiration date.
- Store Standard, SP Conjugate, and Biotinylated Antibody at -20°C.
- Store Microplate, Diluent Concentrate (10x), Standard Diluent (1x), Wash Buffer, Stop Solution, and Chromogen Substrate at 2-8°C.
- Unused microplate wells may be returned to the foil pouch with the desiccant packs and resealed. May be stored for up to 30 days in a vacuum desiccator.

#### **Other Supplies Required**

- Microplate reader capable of measuring absorbance at 450 nm
- Pipettes (1-20 µl, 20-200 µl, 200-1000 µl, and multiple channel)
- Deionized or distilled reagent grade water

#### Sample Collection, Preparation, and Storage

- **Plasma:** Collect plasma using one-tenth volume of 0.1 M sodium citrate as an anticoagulant. Centrifuge samples at 3000 x g for 10 minutes and collect plasma. The sample is suggested for use at 1x; however, user should determine optimal dilution factor depending on application needs. The undiluted samples can be stored at -20°C or below for up to 3 months. Avoid repeated freeze-thaw cycles (EDTA or Heparin can also be used as an anticoagulant).
- Serum: Samples should be collected into a serum separator tube. After clot formation, centrifuge samples at 3000 x g for 10 minutes and remove serum. The sample is suggested for use at 1x; however, user should determine optimal dilution factor depending on application needs. The undiluted samples can be stored at -20°C or below for up to 3 months. Avoid repeated freeze-thaw cycles.
- Cell Culture Supernatant: Centrifuge cell culture media at 1500 rpm for 10 minutes at 4°C to remove debris and collect supernatant. If necessary, dilute samples into MIX Diluent; user should determine optimal dilution factor depending on application needs. The undiluted samples can be stored at -80°C. Avoid repeated freeze-thaw cycles.

Applicable samples may also include biofluids, cell culture, and tissue homogenates. If necessary, user should determine optimal dilution factor depending on application needs.

Refer to Dilution Guidelines for further instruction.

	<b>Guidelines for Dilutions of 100-fold or Greater</b> (for reference only; please follow the insert for specific dilution suggested)				
	100x		10000x		
A)	4 μl sample : 396 μl buffer (100x) = 100-fold dilution Assuming the needed volume is less than	A) B)	4 μl sample : 396 μl buffer (100x) 4 μl of A : 396 μl buffer (100x) = 10000-fold dilution		
	or equal to 400 $\mu$ l.		Assuming the needed volume is less than or equal to 400 $\mu$ l.		
	1000x		100000x		
A) B)	4 μl sample : 396 μl buffer (100x) 24 μl of A : 216 μl buffer (10x) = 1000-fold dilution	A) B) C)	4 μl sample : 396 μl buffer (100x) 4 μl of A : 396 μl buffer (100x) 24 μl of B : 216 μl buffer (10x) = 100000-fold dilution		
	Assuming the needed volume is less than or equal to 240 μl.		Assuming the needed volume is less than or equal to 240 $\mu$ l.		

#### **Reagent Preparation**

- Freshly dilute all reagents and bring all reagents to room temperature before use.
- MIX Diluent Concentrate (10x): Dilute the MIX Diluent Concentrate 10fold with reagent grade water to produce a 1x solution. When diluting the concentrate, make sure to rinse the bottle thoroughly to extract any precipitates left in the bottle. Mix the 1x solution gently until the crystals have completely dissolved. Store for up to 30 days at 2-8°C.
- Human IFN alpha-2b Standard: Reconstitute the Human IFN alpha-2b Standard (5600 pg) with 0.7 ml of Standard Diluent to generate an 8000 pg/ml standard stock solution. Allow the vial to sit for 10 minutes with gentle agitation prior to making dilutions. From the standard stock solution (8000 pg/ml), dilute 4-fold with MIX Diluent to produce a 2000 pg/ml standard working solution. Prepare duplicate or triplicate standard points by serially diluting the standard working solution (2000 pg/ml) 2-fold with equal volume of MIX Diluent to produce 1000, 500, 250, 125, 62.5, and 31.25 pg/ml solutions. MIX Diluent serves as the zero standard (0 pg/ml). Aliquot remaining stock solution to limit repeated freeze-thaw cycles. This solution should be stored at -20°C and used within 30 days.

Standard Point	Dilution	[IFN alpha-2b] (pg/ml)
P1	1 part Standard (8000 pg/ml) + 3 parts MIX Diluent	2000
P2	1 part P1 + 1 part MIX Diluent	1000
Р3	1 part P2 + 1 part MIX Diluent	500
P4	1 part P3 + 1 part MIX Diluent	250
P5	1 part P4 + 1 part MIX Diluent	125
P6	1 part P5 + 1 part MIX Diluent	62.5
P7	1 part P6 + 1 part MIX Diluent	31.25
P8	MIX Diluent	0.0

- Biotinylated Human IFN alpha-2b Antibody (50x): Spin down the antibody briefly and dilute the desired amount of the antibody 50-fold with MIX Diluent to produce a 1x solution. The undiluted antibody should be stored at -20°C.
- Wash Buffer Concentrate (20x): Dilute the Wash Buffer Concentrate 20fold with reagent grade water to produce a 1x solution. When diluting the concentrate, make sure to rinse the bottle thoroughly to extract any precipitates left in the bottle. Mix the 1x solution gently until the crystals have completely dissolved.
- SP Conjugate (100x): Spin down the SP Conjugate briefly and dilute the desired amount of the conjugate 100-fold with MIX Diluent to produce a 1x solution. The undiluted conjugate should be stored at -20°C.

#### Assay Procedure

- Prepare all reagents, standard solutions, and samples as instructed. Bring all reagents to room temperature before use. The assay is performed at room temperature (20-25°C).
- Remove excess microplate strips from the plate frame and return them immediately to the foil pouch with desiccants inside. Reseal the pouch securely to minimize exposure to water vapor and store in a vacuum desiccator.
- Add 50 μl of Human IFN alpha-2b Standard or sample to each well. Gently tap plate to thoroughly coat the wells. Break any bubbles that may have formed. Cover wells with a sealing tape and incubate for 2 hours. Start the timer after the last addition.
- Wash the microplate manually or automatically using a microplate washer. Invert the plate and decant the contents; hit 4-5 times on absorbent material to completely remove the liquid. If washing manually, wash five times with 200 µl of Wash Buffer per well. Invert the plate each time and decant the contents; hit 4-5 times on absorbent material to completely remove the liquid. If using a microplate washer,

wash six times with 300  $\mu$ l of Wash Buffer per well; invert the plate and hit 4-5 times on absorbent material to completely remove the liquid.

- Add 50 µl of Biotinylated Human IFN alpha-2b Antibody to each well. Gently tap plate to thoroughly coat the wells. Break any bubbles that may have formed. Cover wells with a sealing tape and incubate for 1 hour.
- Wash the microplate as described above.
- Add 50 µl of SP Conjugate to each well. Gently tap plate to thoroughly coat the wells. Break any bubbles that may have formed. Cover wells with a sealing tape and incubate for 30 minutes. Turn on the microplate reader and set up the program in advance.
- Wash the microplate as described above.
- Add 50 μl of Chromogen Substrate to each well. Gently tap plate to thoroughly coat the wells. Break any bubbles that may have formed. Incubate in ambient light for 15 minutes or until the optimal blue color density develops.
- Add 50 µl of Stop Solution to each well. The color will change from blue to yellow. Gently tap plate to ensure thorough mixing. Break any bubbles that may have formed.
- Read the absorbance on a microplate reader at a wavelength of 450 nm **immediately**. If wavelength correction is available, subtract readings at 570 nm from those at 450 nm to correct optical imperfections. Otherwise, read the plate at 450 nm only. Please note that some unstable black particles may be generated at high concentration points after stopping the reaction for about 10 minutes, which will reduce the readings.

#### Data Analysis

- Calculate the mean value of the duplicate or triplicate readings for each standard and sample.
- To generate a standard curve, plot the graph using the standard concentrations on the x-axis and the corresponding mean 450 nm absorbance (OD) on the y-axis. The best fit line can be determined by regression analysis using log-log or four-parameter logistic curve fit.
- Determine the unknown sample concentration from the Standard Curve and multiply the value by the dilution factor.


#### **Typical Data**


• The typical data is provided for reference only. Individual laboratory means may vary from the values listed. Variations between laboratories may be caused by technique differences.

Standard Point	pg/ml	OD	Average OD	
P1	2000	2.318	2.352	
	2000	2.386	2.002	
P2	1000	1.482	1.524	
٢Z	1000	1.566	1.524	
Р3	500	0.847	0.822	
P3	500	0.797	0.822	
P4	250	0.434	0.455	
P4		0.476	0.455	
DE	125	0.241	0.254	
P5		0.267	0.254	
P6	62.5	0.145	0.151	
PO	02.5	0.157	0.151	
Р7	31.25	0.094	0.097	
۲/	51.25	0.100	0.097	
P8	0.0	0.040	0.042	
٢ð	0.0	0.044	0.042	

#### Standard Curve

• The curve is provided for illustration only. A standard curve should be generated each time the assay is performed.





#### **Performance Characteristics**

- This assay recognizes both natural and recombinant human IFN alpha-2b.
- The minimum detectable dose of human IFN alpha-2b as calculated by 2SD from the mean of a zero standard was established to be 14 pg/ml.

- Intra-assay precision was determined by testing three plasma samples twenty times in one assay.
- Inter-assay precision was determined by testing three plasma samples in twenty assays.

	Intra-Assay Precision			Inter-Assay Precision		
Sample	1	2	3	1	2	3
n	20	20	20	20	20	20
CV (%)	5.5%	6.2%	4.9%	10.1%	11.3%	9.6%
Average CV (%)	5.5%				10.3%	

#### Recovery

Standard Added Value	60 – 1000 pg/ml	
Recovery %	93 - 115%	
Average Recovery %	98%	

#### **Cross-Reactivity**

Species	Cross-Reactivity (%)
Canine	None
Bovine	None
Equine	50%
Monkey	20%
Mouse	None
Rat	20%
Swine	80%
Rabbit	None
Protein	Cross-Reactivity (%)
Interferon alpha-1	None
Interferon alpha-14	None

• 10% FBS in culture media will not affect the assay.

#### Troubleshooting

Issue	Causes	Course of Action
	Use of improper components	<ul> <li>Check the expiration date listed before use.</li> <li>Do not interchange components from different lots.</li> </ul>
Low Precision	Improper wash step	<ul> <li>Check that the correct wash buffer is being used.</li> <li>Check that all wells are empty after aspiration.</li> <li>Check that the microplate washer is dispensing properly.</li> <li>If washing by pipette, check for proper pipetting technique.</li> </ul>

	Splashing of reagents	Pipette properly in a controlled and careful manner.
	while loading wells	
	Inconsistent volumes	<ul> <li>Pipette properly in a controlled and careful manner.</li> </ul>
	loaded into wells	<ul> <li>Check pipette calibration.</li> </ul>
		<ul> <li>Check pipette for proper performance.</li> </ul>
	Insufficient mixing of	<ul> <li>Thoroughly agitate the lyophilized components after</li> </ul>
	reagent dilutions	reconstitution.
		<ul><li>Thoroughly mix dilutions.</li><li>Check the microplate pouch for proper sealing.</li></ul>
	Improperly sealed	<ul> <li>Check the microplate pouch for proper sealing.</li> <li>Check that the microplate pouch has no punctures.</li> </ul>
	microplate	<ul> <li>Check that three desiccants are inside the microplate</li> </ul>
		pouch prior to sealing.
	Microplate was left	Each step of the procedure should be performed
lal	unattended between	uninterrupted.
igi	steps	
Ч	Omission of step	Consult the provided procedure for complete list of steps.
lig	Steps performed in incorrect order	<ul> <li>Consult the provided procedure for the correct order.</li> </ul>
т х х	Insufficient amount of	Check pipette calibration.
v o sit	reagents added to	Check pipette for proper performance.
lly Low o Intensity	wells	
Unexpectedly Low or High Signal Intensity	Wash step was skipped	<ul> <li>Consult the provided procedure for all wash steps.</li> </ul>
tec	Improper wash buffer	<ul> <li>Check that the correct wash buffer is being used.</li> </ul>
ec.	Improper reagent	<ul> <li>Consult reagent preparation section for the correct</li> </ul>
dxa	preparation	dilutions of all reagents.
a d	Insufficient or prolonged incubation	<ul> <li>Consult the provided procedure for correct incubation time.</li> </ul>
	periods	une.
		<ul> <li>Sandwich ELISA: If samples generate OD values higher</li> </ul>
		than the highest standard point (P1), dilute samples
		further and repeat the assay.
Ĕ	Non-optimal sample	Competitive ELISA: If samples generate OD values lower
ve Ve	dilution	than the highest standard point (P1), dilute samples
'n		<ul><li>further and repeat the assay.</li><li>User should determine the optimal dilution factor for</li></ul>
p		samples.
dar	Contamination of	A new tip must be used for each addition of different
anc	reagents	samples or reagents during the assay procedure.
Sta	Contents of wells	<ul> <li>Verify that the sealing film is firmly in place before placing</li> </ul>
Deficient Standard Curve Fit	evaporate	the assay in the incubator or at room temperature.
cie		Pipette properly in a controlled and careful manner.
efi	Improper pipetting	Check pipette calibration.
		Check pipette for proper performance.
	Insufficient mixing of	<ul> <li>Thoroughly agitate the lyophilized components after reconstitution.</li> </ul>
	reagent dilutions	Thoroughly mix dilutions.

#### References

- (1) Goeddel DV et al. (1980) Nature. 287(5781):411-416.
- (2) Radhakrishnan R et al. (1996) Structure. 4(12):1453-1463.
- (3) Quadt-Akabayov SR et al. (2006) Protein Sci. 15(11):2656-2668.
- (4) Ogawa E et al. (2009) Antiviral Res. 83(2):127-134.

Version 1.5